Activation of the STAT1 signalling pathway in lupus nephritis in MRL/lpr mice

Lupus

Volumn 16, Issue 2, 2007, Pages 101-109

  Dong, Jing ^a,b   Wang, Q X ^b   Zhou, C Y ^b   Ma, X F ^b   Zhang, Y C ^a  

^a SHANDONG UNIVERSITY   (China)

^b QINGDAO UNIVERSITY   (China)

Author keywords

Interferons; Lupus nephritis; MRL lpr mice; STAT1; Systemic lupus erythematosus

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; JANUS KINASE; STAT1 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; EXPERIMENTAL MODEL; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; FEMALE; LUPUS NEPHRITIS; MICE; MICE, INBRED MRL LPR; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR;

EID: 33847419628     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203306075383     Document Type: Article

References (38)

1. Nakashima H, Matsuno S, Akahoshi M et al. Association between IFNA genotype and the risk of systemic lupus erythematosus. Clin Rheumatol 2005; 24: 38-40.
2. Qing X, Putterman C. Gene expression profiling in the study of the pathogenesis of systemic lupus erythematosus. Autoimmun Rev 2004; 3: 505-509.
3. Dall'era MC, Cardarelli PM, Preston BT, Witte A, Davis JC Jr. Type 1 interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis 2005; 64: 1692-1697.
4. Hadj-Slimane R, Chelbi-Alix MK, Tovey MG, Bobe P. An essential role for IFN-alpha in the overexpression of Fas ligand on MRL/lpr lymphocytes and on their spontaneous Fas-mediated cytotoxic potential. J Interferon Cytokine Res 2004; 24: 717-728.
5. Kono DH, Baccala R, Theofilopoulos AN. Inhibition of lupus by genetic alteration of the interferon-alpha/beta receptor. Autoimmunity 2003; 36: 503-510.
6. Braun D, Geraldes P, Demengeot J. Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice. J Autoimmun 2003; 20:15-25.
7. Miyake K, Nakashima H, Akahoshi M et al. Genetically determined interferon-gamma production influences the histological phenotype of lupus nephritis. Rheumatology (Oxford) 2002; 41: 518-524.
8. Min DJ, Cho ML, Cho CS et al. Decreased production of interleukin-12 and interferon-gamma is associated with renal involvement in systemic lupus erythematosus. Scand J Rheumatol 2001; 30: 159-163.
9. Bengtsson AA, Sturfelt G, Truedsson L et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000; 9: 664-671.
10. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 2000; 43: 1431-1442.
11. Baechler EC, Batliwalla FM, Karypis G et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003, 100: 2610-2615.
12. Han GM, Chen SL, Shen N, Ye S, Bao CD, Gu YY. Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun 2003, 4: 177-186.
13. Snapper CM, Paul WE. Interferon-γ and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 1987; 236: 944-947.
14. Snapper CM, Peschel C, Paul WE. IFN-γ stimulates IgG2a secretion by murine B cells stimulated with bacterial lipopolysaccharide. J Immunol 1988; 140: 2121-2127.
15. Finkelman FD, Svetic A, Gresser I et al. Regulation by interferon-α of immunoglobulin isotype selection and lymphokine production in mice. J Exp Med 1991; 174: 1179-1188.
16. Le Bon A, Schiavoni G. D'Agostino G, Gresser I, Belardelli F, Tough DF. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001; 14: 461-470.
17. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001; 294: 1540-1543.
18. Haas C, Ryffel B, Le Hir M. IFN-γ is essential for the development of autoimmune glomerulonephritis in MRL/lpr mice. J Immunol 1997; 158: 5484-5491.
19. Nicoletti F, Di Marco R, Zaccone P, et al. Dichotomic effects of IFN-γ on the development of systemic lupus erythematosus like syndrome in MRL-lpr/lpr mice. Eur J Immunol 2000; 30: 438-447.
20. Reilly CM, Olgun S, Goodwin D et al. Interferon regulatory factor-1 gene deletion decreases glomerulonephritis in MRL/lpr mice. Eur J Immunol 2006; 36: 1296-1308.
21. Qing Y, Stark GR. Alternative activation of STAT1 and STAT3 in response to interferon-gamma. J Biol Chem 2004; 279: 41679-41685.
22. de Prati AC, Ciampa AR, Cavalieri E et al. STAT1 as a new molecular target of anti-inflammatory treatment. Curr Med Chem 2005; 12: 1819-1828.
23. Hilton DJ. Negative regulators of cytokine signal transduction. Cell Mol Life Sci 1999; 55: 1568-1577.
24. Song MM, Shuai K. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon mediated antiviral and antiproliferative activities. J Biol Chem 1998; 273: 35056-35062.
25. Gatto L, Berlato C, Poli V et al. Analysis of SOCS-3 promoter responses to interferon gamma. J Biol Chem 2004; 279: 13746-13754.
26. de Hooge AS, van de Loo FA, Koenders MI et al. Local activation of STAT-I and STAT-3 in the inflamed synovium during zymosan-induced arthritis. Arthritis Rheum 2004; 50: 2014-2023.
27. Kasperkovitz PV, Verbeet NL, Smeets TJ et al. Activation of the STAT1 pathway in rheumatoid arthritis. Ann Rheum Dis 2004; 63: 233-239.
28. Gysemans CA, Ladriere L, Callewaert H et al. Disruption of the gamma-interferon signaling pathway at the level of signal transducer and activator of transcription-1 prevents immune destruction of beta-cells. Diabetes 2005; 54: 2396-2403.
29. Schreiber S, Rosenstiel P, Hampe H et al. Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. Gut 2002; 51: 379-385.
30. Quarcoo D, Weixler S, Groneberg D et al. Inhibition of signal transducer and activator of transcription 1 attenuates allergen-induced airway inflammation and hyperreactivity. J Allergy Clin Immunol 2004; 114: 288-295.
31. Reilly CM, Mishra N, Miller JM et al. Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. J Immunol 2004: 173: 4171-4178.
32. Sekine H, Reilly CM, Molano ID et al. Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr Mice. J Immunol 2001; 166: 6444-6451.
33. Mohan C, Adams S, Stanik V, Datta SK. Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med 1993; 177: 1367-1381.
34. Reilly CM, Oates JC, Cook JA, Morrow JD, Halushka PV, Gilkeson GS. Inhibition of mesangial cell nitric oxide in MRL/lpr mice by prostaglandin J2 and proliferator activation receptor-gamma agonists. J Immunol 2000; 164: 1498-1504.
35. Vannay A, Fekete A, Adori C et al. Divergence of renal vascular endothelial growth factor mRNA expression and protein level in post-ischaemic rat kidneys. Exp Physiol 2004; 89: 435-444.
36. Malide D, Russo P, Bendayan M. Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients. Hum Pathol 1995; 26: 558-564.
37. Wong CK, Ho CY, Li EK, Lam CW. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000; 9: 589-593.
38. Amel-Kashipaz MR, Huggins ML, Lanyon P, Robins A, Todd I, Powell RJ. Quantitative and qualitative analysis of the balance between type 1 and type 2 cytokine-producing CD8(-) and CD8(+) T cells in systemic lupus erythematosus. J Autoimmun 2001; 17: 155-163.